URGN Share Price Performance
US$25.87
13.39 (107.29%)
52.9% undervalued intrinsic discount
US$54.96
Fair Value
Price US$25.87
AnalystHighTarget US$54.96
AnalystConsensusTarget US$33.75
AnalystLowTarget US$16.57
Fair ValueUS$54.96
Share Pricen/a
UroGen Pharma Ltd. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
URGN Community Narratives
AN
Fair Value US$54.96 52.9% undervalued intrinsic discount
Aging Demographics And Advanced Therapies Will Reshape Urology Practice
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$33.75 23.3% undervalued intrinsic discount
Office-Based Urology Therapies And Demographic Trends Will Redefine Care
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
Fair Value US$16.57 56.1% overvalued intrinsic discount
Stricter FDA Oversight And Pricing Pressures Will Limit Reach
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Aging Demographics And Advanced Therapies Will Reshape Urology Practice
Key Takeaways Surge in physician demand and favorable reimbursement may lead to accelerated adoption and new revenue streams, boosting retention and future margins. Strong clinical pipeline and commercial momentum position UroGen as an attractive acquisition target, increasing potential for rapid value appreciation.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$54.96
52.9% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
110.46% p.a.
Profit Margin
58.87%
Future PE
7.27x
Share price in 2028
US$66.32
Office-Based Urology Therapies And Demographic Trends Will Redefine Care
Key Takeaways Successful ZUSDURI launch and pipeline expansion position UroGen for significant revenue growth and reduced product dependency. Alignment with industry care trends and robust commercialization strategy support premium pricing and improved long-term profitability.Read more
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
US$33.75
23.3% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
70.04% p.a.
Profit Margin
32.52%
Future PE
15.34x
Share price in 2028
US$40.76
Stricter FDA Oversight And Pricing Pressures Will Limit Reach
Key Takeaways Heightened regulatory scrutiny, pricing pressures, and potential delays in drug approvals threaten revenue growth and could compress future margins. Heavy reliance on a few products and external funding, amid rising competition and alternative therapies, increases financial and market risks.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$16.57
56.1% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
58.63% p.a.
Profit Margin
16.25%
Future PE
18.53x
Share price in 2028
US$19.98
Recently Updated Narratives
AN
Office-Based Urology Therapies And Demographic Trends Will Redefine Care
Fair Value: US$33.75 23.3% undervalued intrinsic discount
13 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Stricter FDA Oversight And Pricing Pressures Will Limit Reach
Fair Value: US$16.57 56.1% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Demographics And Advanced Therapies Will Reshape Urology Practice
Fair Value: US$54.96 52.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
UroGen Pharma Ltd. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -3.52
- 87.95%
- -170.59%
- -105.8%
About URGN
- Founded
- 2004
- Employees
- 287
- CEO
- WebsiteView website
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
